Mild androgen insensitivity syndrome: Difference between revisions

From Wikipedia, the free encyclopedia
Next edit →
Content deleted Content added
VisualWikitext
←Created page with '{{Infobox disease | Name = Mild androgen insensitivity syndrome | Image = Androgen_receptor_3-d_model.jpg | Caption = [[Androgen insens...'
(No difference)

Revision as of 07:29, 1 November 2010

Mild androgen insensitivity syndrome
SpecialtyEndocrinology Edit this on Wikidata

Mild androgen insensitivity syndrome (MAIS) is a condition that results in a mild impairment of the cell's ability to respond to androgens[1][2][3]. The degree of impairment is sufficient to impair spermatogenesis and / or the development of secondary sexual characteristics at puberty in males, but does not affect genital differentiation or development. Female genital and sexual development is not significantly affected by the insensitivity to androgens[3][4]; as such, MAIS is only diagnosed in males[1]. The clinical phenotype associated with MAIS is a normal male habitus with mild spermatogenic defect and / or reduced secondary terminal hair[1][5][6][7][8][9].

MAIS is one of three types of androgen insensitivity syndrome, which is divided into three categories that are differentiated by the degree of genital masculinization: complete androgen insensitivity syndrome (CAIS) is indicated when the external genitalia is that of a normal female, mild androgen insensitivity syndrome (MAIS) is indicated when the external genitalia is that of a normal male, and partial androgen insensitivity syndrome (PAIS) is indicated when the external genitalia is partially, but not fully masculinized [1][2][5][6][7][10][11][12][13].

Androgen insensitivity syndrome is the largest single entity that leads to 46,XY undermasculinization [14].

Signs and symptoms

Mild androgen insensitivity syndrome (MAIS) presenting with a mild impairment of virilization in a 23-year-old man[15].

Individuals with mild (or minimal) androgen insensitivity syndrome (grade 1 on the Quigley scale) are born phenotypically male, with fully masculinized genitalia; this category of androgen insensitivity is diagnosed when the degree of androgen insensitivity in an individual with a 46,XY karyotype is great enough to impair virilization or spermatogenesis, but is not great enough to impair normal male genital development [1][5][6][9]. MAIS is the mildest and least known form of androgen insensitivity syndrome [5][16].

The existence of a variant of androgen insensitivity that solely affected spermatogenesis was theoretical at first [17]. Cases of phenotypically normal males with isolated spermatogenic defect due to AR mutation were first detected as the result of male infertility evaluations [1][13][18][19]. Until then, early evidence in support of the existence of MAIS was limited to cases involving a mild defect in virilization [15][20], although some of these early cases made allowances for some degree of impairment of genital masculinization, such as hypospadias or micropenis [21][22][23]. It is estimated that 2-3% of infertile men have AR gene mutations [6].

Examples of MAIS phenotypes include isolated infertility (oligospermia or azoospermia) [5][7], mild gynecomastia in young adulthood, decreased secondary terminal hair, high pitched voice, or minor hypospadias repair in childhood [1][24]. The external male genitalia (penis, scrotum, and urethra) are otherwise normal in individuals with MAIS [1][5][6][9]. Internal genitalia, including Wolffian structures (the epididymides, vasa deferentia, and seminal vesicles) and the prostate, is also normal, although the bitesticular volume of infertile men (both with and without MAIS) is diminished [6]; male infertility is associated with reduced bitesticular volume, varicocele, retractile testes, low ejaculate volume, male accessory gland infections (MAGI), and mumps orchitis [6]. The incidence of these features in infertile men with MAIS is similar to that of infertile men without MAIS [6]. MAIS is not associated with Müllerian remnants.

Kennedy Disease

Kennedy disease, also known as spinal and bulbar muscular atrophy (SBMA), is a severe neurodegenerative syndrome that is associated with a particular mutation of the androgen receptor's polyglutamine tract called a trinucleotide repeat expansion [25][26]. SBMA results when the length of the polyglutamine tract exceeds 40 repetitions [27].

Although technically a variant of MAIS, SBMA's presentation is not typical of androgen insensitivity; symptoms do not occur until adulthood and include neuromuscular defects as well as signs of androgen inaction [25]. Neuromuscular symptoms include progressive proximal muscle weakness, atrophy, and fasciculations. Symptoms of androgen insensitivity experienced by men with SBMA are also progressive [25] and include testicular atrophy, severe oligospermia or azoospermia, gynecomastia, and feminized skin changes [28] despite elevated androgen levels [1]. Disease onset, which usually affects the proximal musculature first, occurs in the third to fifth decades of life, and is often preceded by muscular cramps on exertion, tremor of the hands, and elevated muscle creatine kinase [29]. SBMA is often misdiagnosed as amyotrophic lateral sclerosis (ALS) (aka. Lou Gehrig's disease) [26].

The symptoms of SBMA are thought to be brought about by two simultaneous pathways involving the toxic misfolding of proteins and loss of AR functionality [1]. The polyglutamine tract in affected pedigrees tends to increase in length over generations, a phenomenon known as "anticipation" [30], leading to an increase in the severity of the disease as well as a decrease in the age of onset for each subsequent generation of a family affected by SBMA [25].

Comorbidity

Histopathology of testicular tissue showing immature germ cells and spermatagonia with decreased tubular diameter. Scattered groups of Leydig cells appearing immature[31].

All forms of androgen insensitivity are associated with infertility, though exceptions have been reported for both the mild and partial forms [4][5][7][32][33][34]. Lifespan is not thought to be affected by AIS [1].

Trinucleotide Satellite Lengths and AR Transcriptional Activity

Main article: Genetics of Androgen Insensitivity Syndrome

The androgen receptor gene contains two polymorphic trinucleotide microsatellites in exon 1 [2]. The first microsatellite (nearest the 5' end) contains 8 [35] to 60 [26][29] repetitions of the glutamine codon "CAG" and is thus known as the polyglutamine tract [3]. The second microsatellite contains 4 [36] to 31 [37] repetitions of the glycine codon "GGC" and is known as the polyglycine tract [38]. The average number of repetitions varies by ethnicity, with Caucasians exhibiting an average of 21 CAG repeats, and Blacks 18 [39]. Disease states are associated with extremes in polyglutamine tract length; prostate cancer [25], hepatocellular carcinoma [40], and mental retardation [35] are associated with too few repetitions, while spinal and bulbar muscular atrophy (SBMA) is associated with a CAG repetition length of 40 or more [27]. Some studies indicate that the length of the polyglutamine tract is inversely correlated with transcriptional activity in the AR protein, and that longer polyglutamine tracts may be associated with infertility [41][42][43] and undermasculinized genitalia [44]. However, other studies have indicated that no such correlation exists [45][46][47][48][49][50]. A comprehensive meta-analysis of the subject published in 2007 supports the existence of the correlation, and concluded that these discrepancies could be resolved when sample size and study design are taken into account [11]. Longer polyglycine tract lengths have also been associated with genital masculinization defects in some [51][52], but not all [53], studies.

Diagnosis

Main article: Diagnosis of Androgen Insensitivity Syndrome

MAIS is only diagnosed in normal phenotypic males, and is not typically investigated except in cases of male infertility [18]. MAIS has a mild presentation that often goes unnoticed and untreated [15]; even with semenological, clinical and laboratory data, it can be difficult to distinguish between men with and without MAIS, and thus a diagnosis of MAIS is not usually made without confirmation of an AR gene mutation [5]. The androgen sensitivity index (ASI), defined as the product of luteinizing hormone (LH) and testosterone (T), is frequently raised in individuals with all forms of AIS, including MAIS, although many individuals with MAIS have an ASI in the normal range [5]. Testosterone levels may be elevated despite normal levels of luteinizing hormone [15][20][24]. Conversion of testosterone (T) to dihydrotestosterone (DHT) may be impaired, although to a lesser extent than is seen in 5α-reductase deficiency [3]. A high ASI in a normal phenotypic male [45], especially when combined with azoospermia or oligospermia [5][7], decreased secondary terminal hair [26], and / or impaired conversion of T to DHT [3], can be indicative of MAIS, and may warrant genetic testing.

Management

Due to its mild presentation, MAIS often goes unnoticed and untreated [15]. Management of MAIS is currently limited to symptomatic management; methods to correct a malfunctioning androgen receptor protein that result from an AR gene mutation are not currently available. Treatment includes surgical correction of mild gynecomastia, minor hypospadias repair, and testosterone supplementation [1][15][54]. Supraphysiological doses of testosterone have been shown to correct diminished secondary sexual characteristics in men with MAIS [15], as well as to reverse infertility due to low sperm count [55][54]. As is the case with PAIS, men with MAIS will experience side effects from androgen therapy (such as the suppression of the hypothalamic-pituitary-gonadal axis) at a higher dosage than unaffected men. Careful monitoring is required to ensure the safety and efficacy of treatment [56][15][57]. Regular breast [56] and prostate [58] examinations may be necessary due to comorbid association with breast and prostate cancers.

References

  1. ^ a b c d e f g h i j k l Hughes IA, Deeb A (2006). "Androgen resistance". Best Pract. Res. Clin. Endocrinol. Metab. 20 (4): 577–98. doi:10.1016/j.beem.2006.11.003. PMID 17161333. {{cite journal}}: Unknown parameter |month= ignored (help)
  2. ^ a b c Galani A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kalpini-Mavrou A (2008). "Androgen insensitivity syndrome: clinical features and molecular defects". Hormones (Athens). 7 (3): 217–29. PMID 18694860.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ a b c d e Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS (1995). "Androgen receptor defects: historical, clinical, and molecular perspectives". Endocr. Rev. 16 (3): 271–321. PMID 7671849. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  4. ^ a b Giwercman YL, Nordenskjöld A, Ritzén EM, Nilsson KO, Ivarsson SA, Grandell U, Wedell A (2002). "An androgen receptor gene mutation (E653K) in a family with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency as well as in partial androgen insensitivity". J. Clin. Endocrinol. Metab. 87 (6): 2623–8. doi:10.1210/jc.87.6.2623. PMID 12050225. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ a b c d e f g h i j Zuccarello D, Ferlin A, Vinanzi C, Prana E, Garolla A, Callewaert L, Claessens F, Brinkmann AO, Foresta C (2008). "Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility". Clin. Endocrinol. (Oxf). 68 (4): 580–8. doi:10.1111/j.1365-2265.2007.03069.x. PMID 17970778. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ a b c d e f g h Ferlin A, Vinanzi C, Garolla A, Selice R, Zuccarello D, Cazzadore C, Foresta C (2006). "Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations". Clin. Endocrinol. (Oxf). 65 (5): 606–10. doi:10.1111/j.1365-2265.2006.02635.x. PMID 17054461. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  7. ^ a b c d e Stouffs K, Tournaye H, Liebaers I, Lissens W (2009). "Male infertility and the involvement of the X chromosome". Hum. Reprod. Update. 15 (6): 623–37. doi:10.1093/humupd/dmp023. PMID 19515807.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Giwercman YL, Nikoshkov A, Byström B, Pousette A, Arver S, Wedell A (2001). "A novel mutation (N233K) in the transactivating domain and the N756S mutation in the ligand binding domain of the androgen receptor gene are associated with male infertility". Clin. Endocrinol. (Oxf). 54 (6): 827–34. doi:10.1046/j.1365-2265.2001.01308.x. PMID 11422119. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  9. ^ a b c Lund A, Juvonen V, Lähdetie J, Aittomäki K, Tapanainen JS, Savontaus ML (2003). "A novel sequence variation in the transactivation regulating domain of the androgen receptor in two infertile Finnish men". Fertil. Steril. 79 Suppl 3: 1647–8. PMID 12801573. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  10. ^ Ozülker T, Ozpaçaci T, Ozülker F, Ozekici U, Bilgiç R, Mert M (2010). "Incidental detection of Sertoli-Leydig cell tumor by FDG PET/CT imaging in a patient with androgen insensitivity syndrome". Ann Nucl Med. 24 (1): 35–9. doi:10.1007/s12149-009-0321-x. PMID 19957213. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  11. ^ a b Davis-Dao CA, Tuazon ED, Sokol RZ, Cortessis VK (2007). "Male infertility and variation in CAG repeat length in the androgen receptor gene: a meta-analysis". J. Clin. Endocrinol. Metab. 92 (11): 4319–26. doi:10.1210/jc.2007-1110. PMID 17684052. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  12. ^ Kawate H, Wu Y, Ohnaka K, Tao RH, Nakamura K, Okabe T, Yanase T, Nawata H, Takayanagi R (2005). "Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients". J. Clin. Endocrinol. Metab. 90 (11): 6162–9. doi:10.1210/jc.2005-0179. PMID 16118342. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  13. ^ a b Gottlieb B, Lombroso R, Beitel LK, Trifiro MA (2005). "Molecular pathology of the androgen receptor in male (in)fertility". Reprod. Biomed. Online. 10 (1): 42–8. doi:10.1016/S1472-6483(10)60802-4. PMID 15705293. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  14. ^ Ahmed SF, Cheng A, Hughes IA (1999). "Assessment of the gonadotrophin-gonadal axis in androgen insensitivity syndrome". Arch. Dis. Child. 80 (4): 324–9. doi:10.1136/adc.80.4.324. PMC 1717906. PMID 10086936. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  15. ^ a b c d e f g h Pinsky L, Kaufman M, Killinger DW (1989). "Impaired spermatogenesis is not an obligate expression of receptor-defective androgen resistance". Am. J. Med. Genet. 32 (1): 100–4. doi:10.1002/ajmg.1320320121. PMID 2705470. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  16. ^ Wang Q, Ghadessy FJ, Yong EL (1998). "Analysis of the transactivation domain of the androgen receptor in patients with male infertility". Clin. Genet. 54 (3): 185–92. doi:10.1111/j.1399-0004.1998.tb04282.x. PMID 9788719. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  17. ^ Wang Q, Ghadessy FJ, Trounson A, de Kretser D, McLachlan R, Ng SC, Yong EL (1998). "Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation". J. Clin. Endocrinol. Metab. 83 (12): 4303–9. doi:10.1210/jc.83.12.4303. PMID 9851768. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  18. ^ a b Oakes MB, Eyvazzadeh AD, Quint E, Smith YR (2008). "Complete androgen insensitivity syndrome--a review". J Pediatr Adolesc Gynecol. 21 (6): 305–10. doi:10.1016/j.jpag.2007.09.006. PMID 19064222. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  19. ^ Yong EL, Loy CJ, Sim KS (2003). "Androgen receptor gene and male infertility". Hum. Reprod. Update. 9 (1): 1–7. doi:10.1093/humupd/dmg003. PMID 12638777.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  20. ^ a b Grino PB, Griffin JE, Cushard WG, Wilson JD (1988). "A mutation of the androgen receptor associated with partial androgen resistance, familial gynecomastia, and fertility". J. Clin. Endocrinol. Metab. 66 (4): 754–61. doi:10.1210/jcem-66-4-754. PMID 3346354. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  21. ^ Shkolny DL, Beitel LK, Ginsberg J, Pekeles G, Arbour L, Pinsky L, Trifiro MA (1999). "Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively". J. Clin. Endocrinol. Metab. 84 (2): 805–10. doi:10.1210/jc.84.2.805. PMID 10022458. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  22. ^ Pinsky L, Kaufman M, Killinger DW, Burko B, Shatz D, Volpé R (1984). "Human minimal androgen insensitivity with normal dihydrotestosterone-binding capacity in cultured genital skin fibroblasts: evidence for an androgen-selective qualitative abnormality of the receptor". Am. J. Hum. Genet. 36 (5): 965–78. PMC 1684524. PMID 6333813. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  23. ^ Tsukada T, Inoue M, Tachibana S, Nakai Y, Takebe H (1994). "An androgen receptor mutation causing androgen resistance in undervirilized male syndrome". J. Clin. Endocrinol. Metab. 79 (4): 1202–7. doi:10.1210/jc.79.4.1202. PMID 7962294. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  24. ^ a b Zenteno JC, Chávez B, Vilchis F, Kofman-Alfaro S (2002). "Phenotypic heterogeneity associated with identical mutations in residue 870 of the androgen receptor". Horm. Res. 57 (3–4): 90–3. doi:10.1159/000057958. PMID 12006704.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  25. ^ a b c d e Casella R, Maduro MR, Lipshultz LI, Lamb DJ (2001). "Significance of the polyglutamine tract polymorphism in the androgen receptor". Urology. 58 (5): 651–6. doi:10.1016/S0090-4295(01)01401-7. PMID 11711330. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  26. ^ a b c d Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E, Tardieu S, Chadarevian R, Giral P, Turpin G (2002). "A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length". J. Clin. Endocrinol. Metab. 87 (8): 3893–901. doi:10.1210/jc.87.8.3893. PMID 12161529. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  27. ^ a b La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991). "Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy". Nature. 352 (6330): 77–9. doi:10.1038/352077a0. PMID 2062380. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  28. ^ Arbizu T, Santamaría J, Gomez JM, Quílez A, Serra JP (1983). "A family with adult spinal and bulbar muscular atrophy, X-linked inheritance and associated testicular failure". J. Neurol. Sci. 59 (3): 371–82. PMID 6683750. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  29. ^ a b Choong CS, Wilson EM (1998). "Trinucleotide repeats in the human androgen receptor: a molecular basis for disease". J. Mol. Endocrinol. 21 (3): 235–57. doi:10.1677/jme.0.0210235. PMID 9845666. {{cite journal}}: Unknown parameter |month= ignored (help)
  30. ^ Biancalana V, Serville F, Pommier J, Julien J, Hanauer A, Mandel JL (1992). "Moderate instability of the trinucleotide repeat in spino bulbar muscular atrophy". Hum. Mol. Genet. 1 (4): 255–8. doi:10.1093/hmg/1.4.255. PMID 1303195. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  31. ^ Nichols JL, Bieber EJ, Gell JS. Case of sisters with complete androgen insensitivity syndrome and discordant Müllerian remnants. Fertil Steril. 2009;91:932e15-e18.
  32. ^ Chu J, Zhang R, Zhao Z, Zou W, Han Y, Qi Q, Zhang H, Wang JC, Tao S, Liu X, Luo Z (2002). "Male fertility is compatible with an Arg(840)Cys substitution in the AR in a large Chinese family affected with divergent phenotypes of AR insensitivity syndrome". J. Clin. Endocrinol. Metab. 87 (1): 347–51. doi:10.1210/jc.87.1.347. PMID 11788673. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  33. ^ Menakaya UA, Aligbe J, Iribhogbe P, Agoreyo F, Okonofua FE (2005). "Complete androgen insensitivity syndrome with persistent Mullerian derivatives: a case report". J Obstet Gynaecol. 25 (4): 403–5. doi:10.1080/01443610500143226. PMID 16091340. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  34. ^ Giwercman A, Kledal T, Schwartz M, Giwercman YL, Leffers H, Zazzi H, Wedell A, Skakkebaek NE (2000). "Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene". J. Clin. Endocrinol. Metab. 85 (6): 2253–9. doi:10.1210/jc.85.6.2253. PMID 10852459. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  35. ^ a b Kooy RF, Reyniers E, Storm K, Vits L, van Velzen D, de Ruiter PE, Brinkmann AO, de Paepe A, Willems PJ (1999). "CAG repeat contraction in the androgen receptor gene in three brothers with mental retardation". Am. J. Med. Genet. 85 (3): 209–13. doi:10.1002/(SICI)1096-8628(19990730)85:3<209::AID-AJMG4>3.0.CO;2-2. PMID 10398229. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  36. ^ Audi L, Fernández-Cancio M, Carrascosa A; et al. (2010). "Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development". J. Clin. Endocrinol. Metab. 95 (4): 1876–88. doi:10.1210/jc.2009-2146. PMID 20150575. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  37. ^ Lumbroso R, Beitel LK, Vasiliou DM, Trifiro MA, Pinsky L (1997). "Codon-usage variants in the polymorphic (GGN)n trinucleotide repeat of the human androgen receptor gene". Hum. Genet. 101 (1): 43–6. doi:10.1007/s004390050583. PMID 9385367. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  38. ^ Gottlieb B, Pinsky L, Beitel LK, Trifiro M (1999). "Androgen insensitivity". Am. J. Med. Genet. 89 (4): 210–7. doi:10.1002/(SICI)1096-8628(19991229)89:4<210::AID-AJMG5>3.0.CO;2-P. PMID 10727996. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  39. ^ Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (1992). "Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups". Genomics. 12 (2): 241–53. doi:10.1016/0888-7543(92)90371-X. PMID 1740333. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  40. ^ Yeh SH, Chiu CM, Chen CL, Lu SF, Hsu HC, Chen DS, Chen PJ (2007). "Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma". Int. J. Cancer. 120 (8): 1610–7. doi:10.1002/ijc.22479. PMID 17230529. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  41. ^ Casella R, Maduro MR, Misfud A, Lipshultz LI, Yong EL, Lamb DJ (2003). "Androgen receptor gene polyglutamine length is associated with testicular histology in infertile patients". J. Urol. 169 (1): 224–7. doi:10.1097/01.ju.0000035361.18870.6e. PMID 12478141. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  42. ^ Dowsing AT, Yong EL, Clark M, McLachlan RI, de Kretser DM, Trounson AO (1999). "Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene". Lancet. 354 (9179): 640–3. doi:10.1016/S0140-6736(98)08413-X. PMID 10466666. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  43. ^ Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL (1997). "Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility". J. Clin. Endocrinol. Metab. 82 (11): 3777–82. doi:10.1210/jc.82.11.3777. PMID 9360540. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  44. ^ Lim HN, Chen H, McBride S, Dunning AM, Nixon RM, Hughes IA, Hawkins JR (2000). "Longer polyglutamine tracts in the androgen receptor are associated with moderate to severe undermasculinized genitalia in XY males". Hum. Mol. Genet. 9 (5): 829–34. doi:10.1093/hmg/9.5.829. PMID 10749991. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  45. ^ a b Hiort O, Holterhus PM, Horter T, Schulze W, Kremke B, Bals-Pratsch M, Sinnecker GH, Kruse K (2000). "Significance of mutations in the androgen receptor gene in males with idiopathic infertility". J. Clin. Endocrinol. Metab. 85 (8): 2810–5. doi:10.1210/jc.85.8.2810. PMID 10946887. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  46. ^ Kukuvitis A, Georgiou I, Bouba I, Tsirka A, Giannouli CH, Yapijakis C, Tarlatzis B, Bontis J, Lolis D, Sofikitis N, Papadimas J (2002). "Association of oestrogen receptor alpha polymorphisms and androgen receptor CAG trinucleotide repeats with male infertility: a study in 109 Greek infertile men". Int. J. Androl. 25 (3): 149–52. doi:10.1046/j.1365-2605.2002.00339.x. PMID 12031042. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  47. ^ von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni M, Nieschlag E (2001). "Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men". J. Clin. Endocrinol. Metab. 86 (6): 2585–90. doi:10.1210/jc.86.6.2585. PMID 11397858. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  48. ^ Rajpert-De Meyts E, Leffers H, Petersen JH, Andersen AG, Carlsen E, Jørgensen N, Skakkebaek NE (2002). "CAG repeat length in androgen-receptor gene and reproductive variables in fertile and infertile men". Lancet. 359 (9300): 44–6. doi:10.1016/S0140-6736(02)07280-X. PMID 11809188. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  49. ^ Hiort O, Horter T, Schulze W, Kremke B, Sinnecker GH (1999). "Male infertility and increased risk of diseases in future generations". Lancet. 354 (9193): 1907–8. PMID 10584751. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  50. ^ Muroya K, Sasagawa I, Suzuki Y, Nakada T, Ishii T, Ogata T (2001). "Hypospadias and the androgen receptor gene: mutation screening and CAG repeat length analysis". Mol. Hum. Reprod. 7 (5): 409–13. doi:10.1093/molehr/7.5.409. PMID 11331662. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  51. ^ Radpour R, Rezaee M, Tavasoly A, Solati S, Saleki A (2007). "Association of long polyglycine tracts (GGN repeats) in exon 1 of the androgen receptor gene with cryptorchidism and penile hypospadias in Iranian patients". J. Androl. 28 (1): 164–9. doi:10.2164/jandrol.106.000927. PMID 16957138.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  52. ^ Aschim EL, Nordenskjöld A, Giwercman A, Lundin KB, Ruhayel Y, Haugen TB, Grotmol T, Giwercman YL (2004). "Linkage between cryptorchidism, hypospadias, and GGN repeat length in the androgen receptor gene". J. Clin. Endocrinol. Metab. 89 (10): 5105–9. doi:10.1210/jc.2004-0293. PMID 15472213. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  53. ^ Rajender S, Rajani V, Gupta NJ, Chakravarty B, Singh L, Thangaraj K (2006). "No association of androgen receptor GGN repeat length polymorphism with infertility in Indian men". J. Androl. 27 (6): 785–9. doi:10.2164/jandrol.106.000166. PMID 16809273.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  54. ^ a b Yong EL, Ng SC, Roy AC, Yun G, Ratnam SS (1994). "Pregnancy after hormonal correction of severe spermatogenic defect due to mutation in androgen receptor gene". Lancet. 344 (8925): 826–7. doi:10.1016/S0140-6736(94)92385-X. PMID 7993455. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  55. ^ Hughes IA, Houk C, Ahmed SF, Lee PA (2006). "Consensus statement on management of intersex disorders". Arch. Dis. Child. 91 (7): 554–63. doi:10.1136/adc.2006.098319. PMC 2082839. PMID 16624884. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  56. ^ a b Weidemann W, Peters B, Romalo G, Spindler KD, Schweikert HU (1998). "Response to androgen treatment in a patient with partial androgen insensitivity and a mutation in the deoxyribonucleic acid-binding domain of the androgen receptor". J. Clin. Endocrinol. Metab. 83 (4): 1173–6. doi:10.1210/jc.83.4.1173. PMID 9543136. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  57. ^ Tincello DG, Saunders PT, Hodgins MB, Simpson NB, Edwards CR, Hargreaves TB, Wu FC (1997). "Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome". Clin. Endocrinol. (Oxf). 46 (4): 497–506. doi:10.1046/j.1365-2265.1997.1140927.x. PMID 9196614. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  58. ^ Nieschlag E (2006). "Testosterone treatment comes of age: new options for hypogonadal men". Clin. Endocrinol. (Oxf). 65 (3): 275–81. doi:10.1111/j.1365-2265.2006.02618.x. PMID 16918944. {{cite journal}}: Unknown parameter |month= ignored (help)

External links

Information

This template is no longer used; please see Template:Endocrine pathology for a suitable replacement

Retrieved from "https://en.wikipedia.org/w/index.php?title=Mild_androgen_insensitivity_syndrome&oldid=394129095"